• One sample, one run, one instrument; increases efficiency in triaging chest pain patients
• Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
• Single and ready to use TestPak™ Cartridges
  • No reconstitution
  • No warming to room temperature
  • Reduction in reagent waste
  • Reduction in contamination
• Heparinized whole blood samples
• Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility
   

CK-MB is found primarily in cardiac tissue.¹ CK-MB can be detected at elevated concentrations following myocardial damage. Abnormal plasma CK-MB concentrations are often associated with ischemia or necrotic heart injury. The increase in CK-MB concentration is often evident within 3 to 6 hours following onset of chest pain, reaching peak concentrations within 12 to 24 hours. CK-MB concentrations will generally return to normal within 24 to 72 hours.² The determination of CK-MB is most beneficial when samples have been drawn at appropriate time intervals post onset of chest pain.

• One sample, one run, one instrument; increases efficiency in triaging chest pain patients
• Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
• Laboratory quality performance and quantitative results from whole blood in the near-patient care setting
• Single and ready to use TestPak™ Cartridges
            o No reconstitution
            o No warming to room temperature
            o Reduction in reagent waste
            o Reduction in contamination
• Heparinized whole blood samples
• Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility 

Following myocadial necrosis associated with myocardial infarction (MI), myoglobin is one of the first markers to rise above normal levels, increasing measurably above baseline within 2-4 hours post-infarct, peaking at 9-12 hours, and returning to baseline within 24-36 hours.^1,2 In the absence of skeletal muscle trauma or other factors associated with a non-cardiac related increase in circulating myoglobin, myoglobin levels have been used as an early marker for MI.^3,4 A number of reports suggest the measurement of myoglobin as a diagnostic aid in “ruling-out” myocardial infarction with negative predictive values of up to 100% reported at certain time periods after onset of symptoms.

• One sample, one run, one instrument; increases efficiency in triaging chest pain patients
• Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
• Single and ready to use TestPak™ Cartridges
           o No reconstitution
           o No warming to room temperature
           o Reduction in reagent waste
           o Reduction in contamination
• Heparinized whole blood samples
• Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility 

Measurements of NT-proBNP are used as an aid in the diagnosis of individuals suspected of having congestive heart failure (CHF). Other potential clinical uses of NT-proBNP are risk stratification of patients with acute coronary syndrome (ACS) and CHF, as well as treatment and monitoring in patients with left ventricular dysfunction (LVD).

• Rapid turnaround time—in as little as 14 minutes (with onboard centrifugation)
• Single and ready-to-use TestPak™ cartridges
              o  No reconstitution
              o  No warming to room temperature
• Heparinized whole-blood samples
              o  D-dimer and cardiac markers—one sample, one run, one instrument
• Substantial savings potential
              o  Single-use TestPak™ cartridges significantly reduce contamination and
                  open stability issues, reducing reagent waste.
              o  Electronic QC (System Check) satisfies daily routine QC requirements,
                  permitting liquid QC flexibility.
               o  A negative D-dimer test in conjunction with a low pretest probability                    score can exclude PE and may reduce unnecessary diagnostic imaging                  procedures. 

• Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
• Single and ready to use TestPak™ Cartridges
  • No reconstitution
  • No warming to room temperature
  • Reduction in reagent waste
  • Reduction in contamination

• Heparinized whole blood samples
• Dual monoclonal antibody allows the assay to measure total βhCG in the sample
• Measures total βhCG – the intact hCG dimer, as well as the free beta subunit
• Closed container sampling enhances efficiency and safety
• Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility

hCG hormone is produced by the placenta as soon as the fertilized ovum is implanted into the uterine wall. The presence of βhCG in plasma shortly after conception, followed by its rapid rise in concentration, makes it an excellent marker for confirmation of pregnancy. Physiologically, hCG appears to maintain the corpus luteum and support the endometrium. Levels increase to a peak concentration during the first trimester, then decrease and plateau during the remainder of the pregnancy. hCG circulates as the intact molecule in the serum of normal women who have an uncomplicated pregnancy.